| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/29/1999 | WO1999037319A1 Method for treating inflammatory diseases using heat shock proteins |
| 07/29/1999 | WO1999037311A1 Cellulose derivatives and colorectal cancer risk reduction |
| 07/29/1999 | WO1999037302A1 Extended release tiagabine formulations with reduced side-effects |
| 07/29/1999 | WO1999037300A1 Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
| 07/29/1999 | WO1999037297A1 Pig appeasing pheromones to decrease stress, anxiety and aggressiveness |
| 07/29/1999 | WO1999037294A2 Mitochondria protecting agents for treating mitochondria associated diseases |
| 07/29/1999 | WO1999037290A1 Novel dosage form |
| 07/29/1999 | WO1999037289A1 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| 07/29/1999 | WO1999037282A2 Reduced lipid flowable cosmetic or dermatological preparations |
| 07/29/1999 | WO1999037275A2 COSMETIC OR PHARMACEUTICAL PREPARATIONS WITH A LESS STICKY FEEL, CONTAINING GLYCERIN ESTERS OF α-HYDROXY CARBOXYLIC ACIDS AND SATURED FATTY ACIDS |
| 07/29/1999 | WO1999037273A2 Cosmetic and dermatological preparations containing higher electrolyte concentrations |
| 07/29/1999 | WO1999028471A3 ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
| 07/29/1999 | WO1999025384A3 Multimeric tethered ligands and their use in receptor-ligand interactions |
| 07/29/1999 | WO1999012968A3 Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response |
| 07/29/1999 | DE19802708A1 Use of 1-hydroxy-2-pyridone compounds with powder base for treatment of lower leg ulcers and decubitus ulcers |
| 07/29/1999 | DE19802206A1 Stable cosmetic or dermatological composition with low viscosity |
| 07/29/1999 | DE19802205A1 Cosmetic or dermatological composition with electrolyte-containing aqueous phase, stable against phase separation, e.g. sunscreens |
| 07/29/1999 | DE19802204A1 Cosmetic or pharmacological oil in water emulsions with reduced stickiness |
| 07/29/1999 | CA2319131A1 Mitochondria protecting agents for treating mitochondria associated diseases |
| 07/29/1999 | CA2319113A1 Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| 07/29/1999 | CA2319000A1 Prostheses with associated growth factors |
| 07/29/1999 | CA2318448A1 Extended release tiagabine formulations with reduced side-effects |
| 07/29/1999 | CA2318352A1 Diagnosis and treatment of aur1 and/or aur2 related disorders |
| 07/29/1999 | CA2318263A1 Method for treating inflammatory diseases using heat shock proteins |
| 07/29/1999 | CA2318257A1 Novel dosage form |
| 07/29/1999 | CA2317744A1 Cellulose derivatives and colorectal cancer risk reduction |
| 07/29/1999 | CA2260610A1 Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| 07/28/1999 | EP0931836A1 Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof |
| 07/28/1999 | EP0931831A2 Modified catalase, a composition thereof and process for preparing the catalase |
| 07/28/1999 | EP0931552A2 Process for preparation of solid dosage forms |
| 07/28/1999 | EP0931545A2 Droloxifene pharmaceutical compositions |
| 07/28/1999 | EP0930936A1 Method for preparing microcapsules of active substances coated with a polymer and novel microcapsules in particular resulting from the method |
| 07/28/1999 | EP0930895A1 Preparation of protein/polysaccharide conjugate vaccines using homobifunctional and heterobifunctional vinylsulfones |
| 07/28/1999 | EP0930893A1 Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| 07/28/1999 | EP0930892A1 Cytokine enhanced immunotherapy for brain tumors |
| 07/28/1999 | EP0930886A1 Formulation for use in the prevention of pathogen induced diseases including hiv and hsv |
| 07/28/1999 | EP0930885A1 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus |
| 07/28/1999 | EP0930873A1 Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
| 07/28/1999 | EP0865463B1 Process for the preparation of porous polyyolefin particles |
| 07/28/1999 | EP0743958A4 Non-viral vector |
| 07/28/1999 | CN1224360A Hydrophobic preparations contg. medium chain monoglycerides |
| 07/28/1999 | CN1224358A Non-aqueous polar aprotic peptide formulations |
| 07/28/1999 | CN1224357A Aqueous formulations of peptides |
| 07/28/1999 | CN1224356A Non-aqueous protic peptide formulations |
| 07/28/1999 | CN1224355A Injections contg. lipid A analogues and process for preparation thereof |
| 07/28/1999 | CN1224351A Pharmaceutical preparation contg. nimesulide for oral administration |
| 07/28/1999 | CN1224349A Intraorally rapidly disintegrable tablet |
| 07/28/1999 | CN1224346A Lubrication assistant and process for preparation of ethyl stearate used therein |
| 07/28/1999 | CN1224032A Use of isoindolinone derivatives as stabilizers for organic materials |
| 07/28/1999 | CN1223853A Cosmetic and pharmaceutical preparations comprising ascorbic acid derivatives |
| 07/28/1999 | CN1044320C Semduramicin premix preparing process |
| 07/27/1999 | US5929177 Block polymer having functional groups at both ends |
| 07/27/1999 | US5929115 Aqueous mixture containing diclofenac sodium, cyclodextrin, polyvinyl pyrrolidone and one of benzethonium chloride or benzalkonium chloride; storage stability |
| 07/27/1999 | US5929051 Aloe pectin contains 3-o-methyl rhamnose, being capable of forming gel in presence of calcium salt; temperature reversible forms solution at room temperature; used as controlled release agent |
| 07/27/1999 | US5929048 Treatment of conditions and disease |
| 07/27/1999 | US5929028 Liquid gonadotropin containing formulations |
| 07/27/1999 | US5929027 Physiologically active polypeptide-containing pharmaceutical composition |
| 07/27/1999 | US5928958 Superparamagnetic particles, process for their manufacture and usage |
| 07/27/1999 | US5928873 Testing extraintestinal tissues or body fluids for presence of heat stable toxin receptor protein, comparing to negative control assay, increased presence indicates metastasis |
| 07/27/1999 | US5928669 Lymphatic delivery methods |
| 07/27/1999 | US5928667 Drug delivery device and method for employing the same |
| 07/27/1999 | US5928656 Thickeners for products for topical application |
| 07/27/1999 | US5928647 Immunization with non-replicating protein antigens. the compositions of the invention comprise a particulate-protein complex |
| 07/27/1999 | US5928641 Having binding specificity for crossreactive epitopes shared by endoglin expressed on human vascular endothelial cells and endoglin expressed on murine vascular endothelial cells |
| 07/27/1999 | CA2215327C Formulations for lipophilic compounds |
| 07/27/1999 | CA2170622C Oral formulations of an antifungal |
| 07/22/1999 | WO1999036570A2 Transglutaminase linkage of agents to tissue |
| 07/22/1999 | WO1999036514A1 Methods and compositions for gene delivery |
| 07/22/1999 | WO1999036478A1 Color shifting film glitter |
| 07/22/1999 | WO1999036437A1 Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
| 07/22/1999 | WO1999036107A1 Surface coating in spatially controlled patterns |
| 07/22/1999 | WO1999036105A2 USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE |
| 07/22/1999 | WO1999036104A2 Preparation of a lipid blend and a phospholipid suspension containing the lipid blend, and contrast agents based on these |
| 07/22/1999 | WO1999036100A2 Polymeric carrier |
| 07/22/1999 | WO1999036099A1 Sustained release compositions, process for producing the same and utilization thereof |
| 07/22/1999 | WO1999036098A1 Antibacterial composition for topical administration containing antibiotics |
| 07/22/1999 | WO1999036097A1 Disintegrating agent |
| 07/22/1999 | WO1999036096A1 Pharmaceutical formulations and processes for their preparation |
| 07/22/1999 | WO1999036090A1 Oral delivery of nucleic acid vaccines by particulate complexes |
| 07/22/1999 | WO1999036089A1 Genetic immunization with co-delivery of nucleic acid and cytokines in a single vehicle |
| 07/22/1999 | WO1999036075A1 Oral oil sorbing composition |
| 07/22/1999 | WO1999036071A1 Biodegradable polymer matrices for sustained delivery of anesthetics |
| 07/22/1999 | WO1999036065A1 Medicinal compositions |
| 07/22/1999 | WO1999036061A1 Plasticizer and patch containing the plasticizer |
| 07/22/1999 | WO1999036060A1 Oral liquid compositions |
| 07/22/1999 | WO1999036059A2 Microcapsules; process for preparing microcapsules containing a biologically active compound and liquid solution |
| 07/22/1999 | WO1999036055A1 Autoclavable pharmaceutical compositions containing a chelating agent |
| 07/22/1999 | WO1999036031A1 Composition and method for lubricating and protecting the oral cavity using flavored petroleum jelly |
| 07/22/1999 | WO1999029301A3 Lipid compositions and their use |
| 07/22/1999 | WO1999024042A3 Stable antiandrogenic gel composition |
| 07/22/1999 | WO1999022724A3 Extended release formulation containing venlafaxin |
| 07/22/1999 | WO1999018998A3 Delivery system |
| 07/22/1999 | CA2319216A1 Surface coating in spatially controlled patterns |
| 07/22/1999 | CA2318663A1 Methods and compositions for gene delivery |
| 07/22/1999 | CA2318661A1 Transglutaminase linkage of agents to tissue |
| 07/22/1999 | CA2318498A1 Genetic immunization with co-delivery of nucleic acid and cytokines in a single vehicle |
| 07/22/1999 | CA2318493A1 Oral delivery of nucleic acid vaccines by particulate complexes |
| 07/22/1999 | CA2318421A1 Disintegrating agent |
| 07/22/1999 | CA2318284A1 Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
| 07/22/1999 | CA2318236A1 Oral oil sorbing composition |